Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Dec 25.

Published in final edited form as: J Med Chem. 2008 Dec 25;51(24):7806–7819. doi: 10.1021/jm8008629

a) 3-Point pharmacophore generated using known D2/D3 ligands^a b) 3-point pharmacophore derived from D2/D3 ligand hybrid analogues^a c) 3-Point pharmacophore derived from hybrid analogs with corresponding interfeature distances^a

^a Aro/Hyd: Aromatic/Hydrophobic; cat: cationic; Don2: The directional feature towards which the H-bond donor should be oriented. Ar¹ denotes the aromatic ring of either aminotetralin or 2-aminothiazole moieties and Ar² is the phenyl ring attached to one of the piperazine Ns.

a) 3-Point pharmacophore generated using known D2/D3 ligands^a b) 3-point pharmacophore derived from D2/D3 ligand hybrid analogues^a c) 3-Point pharmacophore derived from hybrid analogs with corresponding interfeature distances^a

^a Aro/Hyd: Aromatic/Hydrophobic; cat: cationic; Don2: The directional feature towards which the H-bond donor should be oriented. Ar¹ denotes the aromatic ring of either aminotetralin or 2-aminothiazole moieties and Ar² is the phenyl ring attached to one of the piperazine Ns.